Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications

Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there are several challenges and difficulties that limit their application in clinical settings. This review, which integrates the work of our team and recent advancements...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaotong Wu, Yuhua Meng, Zhimeng Yao, Xiaona Lin, Mengyuan Hu, Songwang Cai, Shegan Gao, Hao Zhang
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825001768
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849727217579327488
author Xiaotong Wu
Yuhua Meng
Zhimeng Yao
Xiaona Lin
Mengyuan Hu
Songwang Cai
Shegan Gao
Hao Zhang
author_facet Xiaotong Wu
Yuhua Meng
Zhimeng Yao
Xiaona Lin
Mengyuan Hu
Songwang Cai
Shegan Gao
Hao Zhang
author_sort Xiaotong Wu
collection DOAJ
description Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there are several challenges and difficulties that limit their application in clinical settings. This review, which integrates the work of our team and recent advancements in this research field, discusses EV-based cancer treatment strategies to guide their clinical application. The following treatment strategies are discussed: 1) leveraging the inherent properties of EVs for the development of cancer treatments; 2) modifying EVs using EV engineering methods to improve drug loading and delivery; 3) targeting key molecules in tumor-derived EV (TDE) synthesis to inhibit their production; and 4) clearing TDEs from the tumor microenvironment. Additionally, on the basis of research into EV-based vaccines and bispecific antibodies, this review elaborates on strategies to enhance antitumor immunity via EVs and discusses engineering modifications that can improve EV targeting ability and stability and the research progress of Artificial intelligence (AI) technology in targeted delivery of EV drugs. Although there are limited strategies for enhancing EV targeting abilities, this review provides an in-depth discussion of prior studies. Finally, this review summarizes the clinical progress on the use of EVs in cancer therapy and highlights challenges that need to be addressed.
format Article
id doaj-art-662765571d3044dbbc1c96112d4eaa81
institution DOAJ
issn 1096-1186
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Pharmacological Research
spelling doaj-art-662765571d3044dbbc1c96112d4eaa812025-08-20T03:09:55ZengElsevierPharmacological Research1096-11862025-07-0121710775110.1016/j.phrs.2025.107751Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applicationsXiaotong Wu0Yuhua Meng1Zhimeng Yao2Xiaona Lin3Mengyuan Hu4Songwang Cai5Shegan Gao6Hao Zhang7State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China; Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China; Department of Urology Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, ChinaCollege of Clinical Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Henan Key Laboratory of Cancer Epigenetics, Luoyang, Henan, China; Corresponding authors.Department of Pathology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China; Department of Pathology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, Guangdong, China; Corresponding author at: Department of Pathology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there are several challenges and difficulties that limit their application in clinical settings. This review, which integrates the work of our team and recent advancements in this research field, discusses EV-based cancer treatment strategies to guide their clinical application. The following treatment strategies are discussed: 1) leveraging the inherent properties of EVs for the development of cancer treatments; 2) modifying EVs using EV engineering methods to improve drug loading and delivery; 3) targeting key molecules in tumor-derived EV (TDE) synthesis to inhibit their production; and 4) clearing TDEs from the tumor microenvironment. Additionally, on the basis of research into EV-based vaccines and bispecific antibodies, this review elaborates on strategies to enhance antitumor immunity via EVs and discusses engineering modifications that can improve EV targeting ability and stability and the research progress of Artificial intelligence (AI) technology in targeted delivery of EV drugs. Although there are limited strategies for enhancing EV targeting abilities, this review provides an in-depth discussion of prior studies. Finally, this review summarizes the clinical progress on the use of EVs in cancer therapy and highlights challenges that need to be addressed.http://www.sciencedirect.com/science/article/pii/S1043661825001768Extracellular vesiclesDrug loadingEV engineeringTargeting EVEV immunotherapyClinical trials
spellingShingle Xiaotong Wu
Yuhua Meng
Zhimeng Yao
Xiaona Lin
Mengyuan Hu
Songwang Cai
Shegan Gao
Hao Zhang
Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
Pharmacological Research
Extracellular vesicles
Drug loading
EV engineering
Targeting EV
EV immunotherapy
Clinical trials
title Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
title_full Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
title_fullStr Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
title_full_unstemmed Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
title_short Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
title_sort extracellular vesicles as nature s nano carriers in cancer therapy insights toward preclinical studies and clinical applications
topic Extracellular vesicles
Drug loading
EV engineering
Targeting EV
EV immunotherapy
Clinical trials
url http://www.sciencedirect.com/science/article/pii/S1043661825001768
work_keys_str_mv AT xiaotongwu extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT yuhuameng extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT zhimengyao extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT xiaonalin extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT mengyuanhu extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT songwangcai extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT shegangao extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications
AT haozhang extracellularvesiclesasnaturesnanocarriersincancertherapyinsightstowardpreclinicalstudiesandclinicalapplications